A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.

Western data on EO-3021 fail to live up to the billing of a Chinese trial.

April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.

A roundup of the first quarter's key oncology drug approvals and rejections.

Keymed’s AstraZeneca-partnered anti-Claudin18.2 ADC looks better than Astellas’s zolbetuximab – albeit on an extremely unreliable metric.

Elevation’s anti-Claudin18.2 antibody-drug conjugate generates some justified optimism, but Zai Lab’s zolbetuximab challenger is out of luck.